A study of the EEG sleep patterns and the sleep and dream experience of a group of schizophrenic patients treated with sulpiride.
The modifications of spontaneous sleep in schizophrenic patients following N-ethyl-2(2-methoxy-5-sulfamido-benzamidomethyl)-pyrrolidine (sulpiride, Dobren) administration are reported in this study. No significant modifications in the quantitative distribution of the various sleep phases (LST, SWS, REM) were observed, while a significant percent increase of SWS was noted, together with a significant decrease in the number of awakenings during the night and an increase of the sleep onset time. The patients' own difficulty to fall asleep, however, decreased significantly, and also a significant increase of dream recall could be observed.
D000328:Adult; D004325:Dreams; D006801:Humans; D008297:Male; D011939:Mental Recall / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy*; D012890:Sleep / Q000187:drug effects*; D012894:Sleep Stages / Q000187:drug effects; D013469:Sulpiride / Q000494:pharmacology*; D014851:Wakefulness / Q000187:drug effects
D013469:Sulpiride